Only show
results from:

Sort results by:

Display preferences
223 results sorted by relevancy Results per page:
Amicus Therapeutics Appoints John F. Crowley Chairman and CEO; -- New Executives Named to Management Team --.
PR Newswire; Jan 24, 2005; 700+ Words ...PRNewswire/ -- Amicus Therapeutics, an emerging biopharmaceutical...and CEO of Orexigen Therapeutics. Prior to this Mr...president of Genzyme Therapeutics and founding president...Novazyme Pharmaceuticals. Amicus develops orally-active...BioMarin Pharmaceutical Inc. from 1998-2004 ...
Amicus Therapeutics Appoints David J. Lockhart Chief Scientific Officer.
PR Newswire; Jan 6, 2006; 700+ Words ...challenges of applying Amicus' technology to a broad...said John Crowley, Amicus chairman and CEO...place at the company." Amicus Therapeutics is a clinical stage company...and CEO of Affymetrix, Inc. said, "David's...
Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference.
PR Newswire; Jan 2, 2008; 700+ Words ...PRNewswire-FirstCall/ -- Amicus Therapeutics Inc. , today announced that John...may be accessed by visiting Amicus' website at http://www...9007, ext. 14, both for Amicus Therapeutics Inc. Web site: http://www...
Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008.
PR Newswire; Feb 7, 2008; 700+ Words ...PRNewswire-FirstCall/ -- Amicus Therapeutics Inc. , today announced that John...may be accessed by visiting Amicus' website at http://www...9007, Ext. 14, both for Amicus Therapeutics Inc. Web site: http://www...
Amicus Therapeutics Initiates Phase I Trial With Lead Compound AT1001 For The Treatment of Fabry Disease.
PR Newswire; Aug 5, 2004; 700+ Words ...Aug. 5 /PRNewswire/ -- Amicus Therapeutics, Inc., an emerging drug development...Clinical Development of Amicus Therapeutics, Inc. "AT1001 is designed to...Chief Executive Officer of Amicus Therapeutics, Inc. "The completion of our...
Amicus Therapeutics Expands Intellectual Property Estate; - Issuance of Fourth U.S. Patent Secures Company's Proprietary Position in Pharmacological Chaperone Technology -.
PR Newswire; Sep 18, 2003; 700+ Words ...BRUNSWICK, N.J., Sept. 18 /PRNewswire/ -- Amicus Therapeutics, Inc., an emerging drug development company focused...Hardman, Ph.D., Chief Executive Officer of Amicus Therapeutics, Inc. "Amicus was founded on the belief that pharmacological...
Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference.
PR Newswire; Feb 1, 2008; 700+ Words ...PRNewswire-FirstCall/ -- Amicus Therapeutics Inc. , today announced that John...may be accessed by visiting Amicus' website at http://www...February 22, 2008. About Amicus Therapeutics Amicus Therapeutics is a biopharmaceutical...
Amicus Therapeutics Announces Preliminary Results of Phase 2 Study with Plicera(TM) for Gaucher Disease.
PR Newswire; Oct 2, 2009; 700+ Words ...Amicus Therapeutics Amicus Therapeutics is a biopharmaceutical...developing novel, oral therapeutics known as pharmacological...increased activity. Amicus is initially targeting...Genetic Therapies, Inc., a wholly-owned...
Amicus Therapeutics Announces Pricing of Initial Public Offering of 5,000,000 Shares of Common Stock.
PR Newswire; May 31, 2007; 700+ Words ...FirstCall/ -- Amicus Therapeutics announced today...00 per share. Amicus has granted the...Morgan Securities Inc., Lazard Capital...closing conditions. Amicus filed a registration...About Amicus Therapeutics Amicus Therapeutics...
Amicus Therapeutics Files For Initial Public Offering.
PR Newswire; Mar 30, 2007; 700+ Words ...March 30 /PRNewswire/ -- Amicus Therapeutics, Inc. today announced that it...Matthew Patterson of Amicus Therapeutics, +1-609-662-2000, or Dan Budwick for Amicus Therapeutics, Inc., +1-212-477-9007...
Amicus Therapeutics Receives U.S. Orphan Drug Designation for AT1001 in the Treatment of Fabry Disease.
PR Newswire; Mar 8, 2004; 700+ Words ...March 8 /PRNewswire/ -- Amicus Therapeutics, Inc., an emerging drug development...Chief Executive Officer of Amicus Therapeutics, Inc. "AT1001 is a small molecule...Chief Executive Officer of Amicus Therapeutics, Inc., +1-732-745-9977...
Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease.
PR Newswire; Aug 4, 2008; 700+ Words ...FirstCall/ -- Amicus Therapeutics , a biopharmaceutical...Phase 3 trial design. Amicus, along with its partner...Genetic Therapies, Inc. ("Shire"), is...previous guidance, Amicus expects to complete...President and CEO of Amicus Therapeutics. "We look forward...
Amicus Therapeutics Announces Third Quarter 2008 Financial Results.
PR Newswire; Nov 3, 2008; 700+ Words ...of strong progress for Amicus as we focused on clinical...President and CEO of Amicus Therapeutics. "In recent months...treatment of Fabry disease. Amicus, along with its partner...Human Genetic Therapies, Inc. ("Shire"), is...
Amicus Therapeutics Announces Second Quarter 2008 Financial Results.
PR Newswire; Aug 7, 2008; 700+ Words ...2008 was significant for Amicus. We initiated a Phase...President and CEO of Amicus Therapeutics. "In the second half...disease. Previously, Amicus announced that it had...Human Genetic Therapies, Inc. ("Shire"), is...
Amicus Therapeutics Raises $31 Million in Series B Financing.
PR Newswire; May 12, 2004; 700+ Words ...May 12 /PRNewswire/ -- Amicus Therapeutics, Inc., an emerging drug development...Chief Executive Officer of Amicus Therapeutics, Inc. "With their commitment...Chief Executive Officer of Amicus Therapeutics, Inc., +1-732-745-9977...
Amicus Therapeutics Appoints Chief Financial Officer.
PR Newswire; Oct 2, 2006; 700+ Words ...PRNewswire/ -- Amicus Therapeutics, a biopharmaceutical...Mr. Dentzer joins Amicus from Biogen Idec Inc., where he served...President and CEO of Amicus. "He is a great...Chicago. About Amicus Therapeutics Amicus Therapeutics...
Amicus Therapeutics Files for Initial Public Offering.
PR Newswire; May 17, 2006; 700+ Words ...CRANBURY, N.J., May 17 /PRNewswire/ -- Amicus Therapeutics, Inc. today announced that it has filed a registration...stock. All shares in the offering will be sold by Amicus Therapeutics. Morgan Stanley will act as sole book-runner...
Amicus Therapeutics Announces Plan to Initiate Phase 1 Study of AT2220 for Pompe Disease.
PR Newswire; Sep 30, 2009; 700+ Words ...Amicus Therapeutics Amicus Therapeutics is a biopharmaceutical...developing novel, oral therapeutics known as pharmacological...increased activity. Amicus is initially targeting...Genetic Therapies, Inc., a wholly-owned...
Amicus Therapeutics Announces Pricing of IPO at $15.00 per Share.
M2 Presswire; May 31, 2007; 700+ Words ...identified, Amicus Therapeutics (NASDAQ: FOLD) due...corporate development. Amicus Therapeutics (NASDAQ: FOLD) announced...15.00 per share. Amicus has granted the underwriters...Morgan Securities Inc., Lazard Capital Markets...
Amicus Therapeutics and Shire plc Enter Into $440 Million ex-US Licensing Agreement to Develop and Commercialize Amigal(TM), Plicera(TM) and At2220.
PR Newswire; Nov 8, 2007; 700+ Words Amicus to Host Conference Call at 8:00 A...Nov. 8 /PRNewswire-FirstCall/ -- Amicus Therapeutics, Inc. announced today that it has entered...subsidiary of Shire plc , to jointly develop Amicus' three lead pharmacological chaperone...
223 results: 1 | 2 | 3 | 4 | 5 | Next >>

Find articles, research, and archives